Title:
【発明の名称】シクロペンチルタキキニン受容体アンタゴニスト
Document Type and Number:
Japanese Patent JP2002534955
Kind Code:
A
Abstract:
The present invention is directed to certain novel compounds represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R<3>, R<6>, R<7>, R<8>, R<11>, R<12>, R<13>, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulation in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
Inventors:
Finke, Paul Yi
Matsukos, Malcolm
Laura Sea, Miura
Mills, Thunder Gee
Caldwell, Charles G
Chien pin
Dorayetto, Philip L
Hail, jeffrey
Holson, edward
Copka, Iho
Alberto, Albert
Matsukos, Malcolm
Laura Sea, Miura
Mills, Thunder Gee
Caldwell, Charles G
Chien pin
Dorayetto, Philip L
Hail, jeffrey
Holson, edward
Copka, Iho
Alberto, Albert
Application Number:
JP51592997A
Publication Date:
October 15, 2002
Filing Date:
October 15, 1996
Export Citation:
Assignee:
Merck End Company, Inc.
International Classes:
A61K31/16; A61K31/215; A61K31/34; A61K31/343; A61K31/381; A61K31/40; A61K31/4015; A61K31/404; A61K31/41; A61K31/4166; A61K31/4178; A61K31/4192; A61K31/42; A61K31/421; A61K31/4245; A61K31/425; A61K31/426; A61K31/427; A61K31/428; A61K31/429; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4439; A61K31/445; A61K31/47; A61K31/505; A61K31/5375; A61K31/5377; A61P1/08; A61P11/06; A61P25/06; A61P29/00; A61P43/00; C07C43/192; C07C43/196; C07C62/32; C07C62/38; C07C69/757; C07C217/52; C07C229/48; C07C233/81; C07C237/06; C07C265/10; C07C271/24; C07C275/26; C07D207/16; C07D207/26; C07D207/38; C07D209/08; C07D211/14; C07D211/16; C07D211/58; C07D211/62; C07D213/30; C07D213/38; C07D213/61; C07D215/18; C07D215/20; C07D233/32; C07D233/61; C07D233/70; C07D233/86; C07D239/26; C07D249/08; C07D249/12; C07D257/04; C07D261/08; C07D263/32; C07D271/06; C07D271/10; C07D277/28; C07D277/64; C07D295/08; C07D295/12; C07D295/18; C07D307/42; C07D307/52; C07D307/64; C07D307/79; C07D307/82; C07D307/92; C07D333/20; C07D333/32; C07D333/38; C07D333/58; C07D401/04; C07D403/10; C07D403/12; C07D405/12; C07D413/10; C07D413/12; C07D417/04; C07D417/10; C07D417/12; C07D513/04; C07D521/00; C07J73/00; (IPC1-7): C07C43/192; A61K31/16; A61K31/215; A61K31/34; A61K31/343; A61K31/381; A61K31/40; A61K31/4015; A61K31/404; A61K31/41; A61K31/4166; A61K31/4178; A61K31/4192; A61K31/42; A61K31/421; A61K31/4245; A61K31/425; A61K31/426; A61K31/427; A61K31/428; A61K31/429; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4439; A61K31/445; A61K31/47; A61K31/505; A61K31/5375; A61K31/5377; A61P1/08; A61P11/06; A61P25/06; A61P29/00; A61P43/00; C07C43/196; C07C62/32; C07C62/38; C07C69/757; C07C217/52; C07C265/10; C07C271/24; C07C275/26; C07D207/16; C07D207/38; C07D209/08; C07D211/14; C07D211/16; C07D211/58; C07D211/62; C07D213/30; C07D213/38; C07D213/61; C07D215/18; C07D215/20; C07D233/32; C07D233/61; C07D233/70; C07D239/26; C07D249/12; C07D257/04; C07D261/08; C07D263/32; C07D271/06; C07D277/28; C07D277/64; C07D295/08; C07D295/12; C07D295/18; C07D307/42; C07D307/79; C07D307/82; C07D333/20; C07D333/32; C07D333/58; C07D401/04; C07D403/10; C07D403/12; C07D405/12; C07D413/10; C07D417/04; C07D417/10; C07D513/04
Attorney, Agent or Firm:
Yoshio Kawaguchi (1 person outside)